enGene Holdings Inc. (NASDAQ:ENGN) Receives Average Recommendation of "Buy" from Analysts

enGene Holdings Inc. (NASDAQ:ENGN - Get Free Report) has received an average recommendation of "Buy" from the eleven ratings firms that are presently covering the stock, Marketbeat.com reports. Ten investment analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $29.78.

A number of analysts recently weighed in on ENGN shares. JMP Securities reaffirmed a "market outperform" rating and issued a $18.00 price objective on shares of enGene in a research note on Monday, December 23rd. Raymond James started coverage on enGene in a research report on Wednesday, November 27th. They set an "outperform" rating and a $23.00 price objective on the stock. HC Wainwright assumed coverage on shares of enGene in a report on Monday, December 23rd. They issued a "buy" rating and a $25.00 target price for the company. Finally, Citizens Jmp raised shares of enGene to a "strong-buy" rating in a research report on Monday, November 18th.

enGene Trading Down 1.8 %

Shares of NASDAQ:ENGN traded down $0.13 during trading on Friday, hitting $7.16. The company had a trading volume of 35,738 shares, compared to its average volume of 96,406. The company has a debt-to-equity ratio of 0.08, a current ratio of 16.87 and a quick ratio of 16.87. The company has a fifty day simple moving average of $7.36 and a two-hundred day simple moving average of $7.52. The stock has a market cap of $316.59 million, a price-to-earnings ratio of -12.34 and a beta of -0.65. enGene has a one year low of $4.42 and a one year high of $18.40.

enGene (NASDAQ:ENGN - Get Free Report) last released its earnings results on Thursday, December 19th. The company reported ($0.34) earnings per share for the quarter, topping analysts' consensus estimates of ($0.40) by $0.06. As a group, equities analysts forecast that enGene will post -1.57 earnings per share for the current year.

Institutional Trading of enGene

A number of hedge funds have recently added to or reduced their stakes in the company. Point72 Asset Management L.P. lifted its position in shares of enGene by 1,410.3% in the third quarter. Point72 Asset Management L.P. now owns 663,000 shares of the company's stock valued at $4,376,000 after acquiring an additional 619,100 shares in the last quarter. Franklin Resources Inc. raised its position in shares of enGene by 48.7% in the third quarter. Franklin Resources Inc. now owns 1,189,952 shares of the company's stock valued at $7,854,000 after buying an additional 389,918 shares during the last quarter. Finally, Wolverine Asset Management LLC purchased a new position in shares of enGene in the third quarter worth about $37,000. 64.16% of the stock is owned by hedge funds and other institutional investors.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.